{"url_path":"/sec/armp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS****","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-060333-index.html","accession_number":"0001104659-26-060333","cik":"0000921114","ticker":"ARMP","issuer_name":"Armata Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921114/0001104659-26-060333-index.html","primary_entity_key":"0000921114","primary_entity_name":"Armata Pharmaceuticals, Inc."},"word_count":1139,"has_tables":true,"body_markdown":"Item 6. EXHIBITS****\n\n​\n\nNumber\n\n  ​ ​ ​\n\nDescription\n\n3.1\n\n​\n\n[Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015)](https://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm).\n\n​\n\n​\n\n​\n\n3.2\n\n​\n\n[Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-37544), filed with the SEC on April 24, 2017](https://www.sec.gov/Archives/edgar/data/921114/000114420417021763/v464998_ex3-1.htm)).\n\n​\n\n​\n\n​\n\n3.3\n\n​\n\n[Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2018)](https://www.sec.gov/Archives/edgar/data/921114/000114420418058340/tv505699_ex3-2.htm).\n\n​\n\n​\n\n​\n\n3.4\n\n​\n\n[Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018)](https://www.sec.gov/Archives/edgar/data/921114/000114420418065017/tv509361_ex3-1.htm).\n\n​\n\n​\n\n​\n\n3.5\n\n​\n\n[Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019)](https://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-1.htm).\n\n​\n\n​\n\n​\n\n39\n\n[Table of Contents](#TOC)\n\n3.6\n\n​\n\n[Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019)](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-1.htm).\n\n​\n\n​\n\n​\n\n3.7\n\n​\n\n[Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 30, 2020)](https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm).\n\n​\n\n​\n\n​\n\n3.8\n\n​\n\n[Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019)](https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm).\n\n​\n\n​\n\n​\n\n3.9\n\n​\n\n[Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2019)](https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm).\n\n​\n\n​\n\n​\n\n3.10\n\n​\n\n[Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 26, 2020)](https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm).\n\n​\n\n​\n\n​\n\n4.1\n\n​\n\nReference is made to Exhibits 3.1 through 3.10.\n\n​\n\n​\n\n​\n\n4.2\n\n​\n\n[Warrant Amendment, dated January 23, 2026 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex4-1.htm)\n\n​\n\n​\n\n​\n\n10.1\n\n​\n\n[First Amendment, dated as of January 23, 2026, to that certain Credit and Security Agreement, dated as of March 12, 2025, by and among the Company, the Guarantors party thereto, and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex10-1.htm)\n\n​\n\n​\n\n​\n\n10.2\n\n​\n\n[Second Amendment, dated as of January 23, 2026, to that certain to that certain Credit and Security Agreement, dated as of March 4, 2024, by and among the Company, the Guarantors party thereto, and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex10-2.htm)\n\n​\n\n​\n\n​\n\n10.3\n\n​\n\n[Fourth Amendment, dated as of January 23, 2026, to that certain Credit and Security Agreement, dated as of July 10, 2023, by and among the Company, the Guarantors party thereto, and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex10-3.htm)\n\n​\n\n​\n\n​\n\n10.4\n\n​\n\n[Fifth Amendment, dated as of January 23, 2026, to that certain Secured Convertible Credit and Security Agreement, dated as of January 10, 2023, by and among the Company, the Guarantors party thereto, and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex10-4.htm)\n\n​\n\n​\n\n​\n\n10.5\n\n​\n\n[Amendment No.2, dated as of January 23, 2026, to that certain Second Amended and Restated Voting Agreement, dated as of February 9, 2022 (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on January 26, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926006446/tm263967d1_ex10-5.htm)\n\n​\n\n​\n\n​\n\n10.6\n\n​\n\n[Credit and Security Agreement, dated as of May 12, 2026 by and among the Company, the Guarantors party thereto, and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 13, 2026).](https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512xex10d1.htm)\n\n​\n\n​\n\n​\n\n31.1\n\n​\n\n[Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)](armp-20260331xex31d1.htm).\n\n​\n\n​\n\n​\n\n31.2\n\n \n\n[Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).](armp-20260331xex31d2.htm)\n\n​\n\n​\n\n​\n\n40\n\n[Table of Contents](#TOC)\n\n32.1†\n\n \n\n[Certification of Principal Executive Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.](armp-20260331xex32d1.htm)\n\n​\n\n​\n\n​\n\n32.2†\n\n \n\n[Certification of Principal Financial Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.](armp-20260331xex32d2.htm)\n\n​\n\n​\n\n​\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n​\n\n​\n\n​\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document.\n\n​\n\n​\n\n​\n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document.\n\n​\n\n​\n\n​\n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document.\n\n​\n\n​\n\n​\n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document.\n\n​\n\n​\n\n​\n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document.\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\n†\n\nThe certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n​\n\n​\n\n​\n\n41\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n​\n\n​\n\nARMATA PHARMACEUTICALS, INC.\n\n​\n\nDate: May 13, 2026\n\nBy\n\n/s/ Deborah L. Birx\n\n​\n\nName: Deborah L. Birx, M.D.\n\n​\n\nTitle: Chief Executive Officer\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nBy\n\n/s/ David House\n\n​\n\n​\n\n​\n\nName: David House\n\n​\n\n​\n\n​\n\nTitle: Senior Vice President, Finance and\n\nPrincipal Financial Officer\n\n​\n\n​\n\n​\n\n(Principal Financial Officer)\n\n​\n\n​\n\n​\n\n​\n\n42"}